文献速递真菌感染

泊沙康唑在异基因造血干细胞移植患者中的群体药代动力学

Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

这项前瞻性观察性药代动力学研究纳入20例异基因造血干细胞移植后早期需从口服改为静脉泊沙康唑的成人患者,建立二室模型并开展蒙特卡罗模拟。模型显示口腔黏膜炎/腹泻影响口服生物利用度;为达到预防Cmin目标(≥0.5和≥0.7 mg/L)的≥90% PTA,口服缓释片需高于现行推荐剂量,而治疗IFD的PK/PD目标两制剂均需增量,伴口腔黏膜炎/腹泻者难以达标。

要点

  • 二室模型纳入口腔黏膜炎/腹泻修正口服生物利用度,最佳描述数据。
  • 预防Cmin≥0.5和≥0.7 mg/L需≥90% PTA时,口服缓释片需高于现行推荐剂量。
  • 治疗IFD的PK/PD目标两制剂均需增量,伴口腔黏膜炎/腹泻者难以达标。

核心结论

  • 作者认为,为增加异基因造血干细胞移植患者达到治疗暴露的比例,预防和治疗IFD均应考虑增加泊沙康唑剂量,尤其是伴黏膜炎和/或腹泻患者的口服制剂。
  • 作者认为,该场景下所有剂型均应考虑进行治疗药物监测。

研究设计与样本

  • 前瞻性观察性药代动力学研究,纳入20例21至70岁异基因造血干细胞移植后早期需从口服改为静脉泊沙康唑的成人患者。
  • 样本用经验证的LC-MS/MS法分析,采用Pmetrics for R进行群体药代动力学分析和蒙特卡罗模拟(n=1000)。

主要发现

  • 二室模型纳入口腔黏膜炎/腹泻修正口服生物利用度,最佳描述数据。
  • 模拟显示,为达到预防Cmin目标(≥0.5和≥0.7 mg/L)的≥90% PTA,口服缓释泊沙康唑需高于现行推荐剂量。
  • 模拟显示,为达到IFD治疗的PK/PD目标,两种制剂均需增加剂量,伴口腔黏膜炎/腹泻患者不太可能达到这些目标。

关键数值与推荐

  • 预防Cmin目标为≥0.5和≥0.7 mg/L,目标PTA为≥90%。
  • 治疗IFD采用PK/PD目标,原文未给出具体数值。

临床怎么用

  • 作者认为,预防和治疗IFD均应考虑增加泊沙康唑剂量,尤其是伴黏膜炎和/或腹泻患者的口服制剂。
  • 作者认为,该场景下所有剂型均应考虑进行治疗药物监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive fungal disease (IFD) in the early post-allogeneic HSCT (alloHCT) period is associated with increased likelihood of catastrophic outcomes. The utility of oral modified release (MR) posaconazole tablets is limited by reduced drug absorption from gastrointestinal toxicity induced by cytotoxic chemotherapy, necessitating a switch to the IV posaconazole formulation. OBJECTIVES: To describe the population pharmacokinetics of posaconazole for oral MR and IV formulations in alloHCT patients and determine dosing regimens likely to achieve therapeutic exposures. METHODS: We performed a prospective observational pharmacokinetic study in adult patients in the early post-alloHCT period requiring a change in posaconazole formulation (oral to IV). Samples were analysed using a validated LC-MS/MS method. Population pharmacokinetic analysis and Monte Carlo simulations (n = 1000) were performed using Pmetrics for R. RESULTS: Twenty patients aged between 21 and 70 years were included in the study. A two-compartment model, incorporating mucositis/diarrhoea to modify the bioavailability for oral administration best described the data. To achieve ≥90% PTA, simulations showed that higher than currently recommended doses of oral MR posaconazole were required for prophylaxis Cmin targets (≥0.5 and ≥0.7 mg/L), while increased doses of both formulations were required for IFD treatment PK/PD targets, with patients experiencing oral mucositis/diarrhoea unlikely to achieve these. CONCLUSIONS: Increased doses of posaconazole should be considered for both prophylaxis and treatment of IFD to increase the proportion of alloHCT patients achieving therapeutic exposures, particularly the oral formulation in patients with mucositis and/or diarrhoea. Posaconazole therapeutic drug monitoring should be considered for all formulations in this setting.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Selby PR, Heffernan AJ, Yeung D, et al. Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients. J Antimicrob Chemother. 2024. PMID: 38217845. doi:10.1093/jac/dkae006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。